GSTP1 Ile105Val polymorphism in astrocytomas and glioblastomas

A.C. Custódio¹, L.O. Almeida¹, G.R. Pinto¹,², M.J. Santos², J.R.W. Almeida², C.A. Clara², J.A. Rey⁴ and C. Casartelli¹

¹Departamento de Genética, Laboratório de Oncogenética, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
²Fundação Pio XII, Hospital de Câncer de Barretos, Barretos, SP, Brasil
³Laboratório de Genética Humana e Biologia Molecular, Universidade Federal do Piauí, Parnaíba, PI, Brasil
⁴Departamento de Cirurgia Experimental, Laboratório de Oncogenética Molecular, Hospital Universitário “La Paz”, Madrid, Espanha

Corresponding author: A.C. Custódio
E-mail: alinecadurin@yahoo.com.br

Received August 12, 2010
Accepted September 11, 2010
Published November 30, 2010
DOI 10.4238/vol9-4gmr971

ABSTRACT. Glutathione S-transferases (GSTs) constitute a superfamily of ubiquitous multifunctional enzymes that are involved in the cellular detoxification of a large number of endogenous and exogenous chemical agents that have electrophilic functional groups. People who have deficiencies in this family of genes are at increased risk of developing some types of tumors. We examined GSTP1 Ile105Val polymorphism using PCR-RFLP in 80 astrocytoma and glioblastoma samples. Patients who had the Val allele of the GSTP1 Ile105Val polymorphism had an increased risk of tumor development (odds ratio = 8.60; 95% confidence interval = 4.74-17.87; P < 0.001). Overall survival of patients did not differ significantly. We suggest that GSTP1 Ile105Val polymorphisms are involved in susceptibility to developing astrocytomas and glioblastomas.

Key words: Polymorphism; GSTP1; Astrocytoma; Glioblastoma